MX2020005547A - Moduladores de la actividad del complemento. - Google Patents

Moduladores de la actividad del complemento.

Info

Publication number
MX2020005547A
MX2020005547A MX2020005547A MX2020005547A MX2020005547A MX 2020005547 A MX2020005547 A MX 2020005547A MX 2020005547 A MX2020005547 A MX 2020005547A MX 2020005547 A MX2020005547 A MX 2020005547A MX 2020005547 A MX2020005547 A MX 2020005547A
Authority
MX
Mexico
Prior art keywords
modulators
complement activity
eculizumab
subjects
methods
Prior art date
Application number
MX2020005547A
Other languages
English (en)
Inventor
Alonso Ricardo
Ramin Farzaneh-Far
Michelle Denise Hoarty
Original Assignee
Ra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ra Pharmaceuticals Inc filed Critical Ra Pharmaceuticals Inc
Publication of MX2020005547A publication Critical patent/MX2020005547A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
    • C12Y301/27005—Pancreatic ribonuclease (3.1.27.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación proporciona métodos para tratar hemoglobinuria paroxística nocturna (PNH) en sujetos con exposición variable a eculizumab mediante la administración de R5000. Los métodos incluyen métodos para cambiar sujetos de tratamiento con eculizumab a R5000.
MX2020005547A 2017-12-04 2018-12-04 Moduladores de la actividad del complemento. MX2020005547A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762594486P 2017-12-04 2017-12-04
US201862629156P 2018-02-12 2018-02-12
US201862685314P 2018-06-15 2018-06-15
US201862769751P 2018-11-20 2018-11-20
PCT/US2018/063719 WO2019112984A1 (en) 2017-12-04 2018-12-04 Modulators of complement activity

Publications (1)

Publication Number Publication Date
MX2020005547A true MX2020005547A (es) 2020-08-20

Family

ID=64734251

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005547A MX2020005547A (es) 2017-12-04 2018-12-04 Moduladores de la actividad del complemento.

Country Status (13)

Country Link
US (1) US20210000927A1 (es)
EP (1) EP3720463A1 (es)
JP (1) JP2021505565A (es)
KR (1) KR20200095485A (es)
CN (1) CN111683672A (es)
BR (1) BR112020010916A2 (es)
CA (1) CA3084043A1 (es)
IL (1) IL274745A (es)
MX (1) MX2020005547A (es)
RU (1) RU2020117578A (es)
SG (1) SG11202005181RA (es)
TW (1) TW201938184A (es)
WO (1) WO2019112984A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
PL2275443T3 (pl) 2008-04-11 2016-05-31 Chugai Pharmaceutical Co Ltd Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
DK3154561T3 (da) 2014-06-12 2019-10-07 Ra Pharmaceuticals Inc Modulering af komplementaktivitet
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
LT3250230T (lt) 2015-01-28 2021-12-27 Ra Pharmaceuticals, Inc. Komplemento aktyvumo moduliatoriai
SG11201804721SA (en) 2015-12-16 2018-07-30 Ra Pharmaceuticals Inc Modulators of complement activity
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
MX2020004284A (es) * 2017-10-26 2020-10-28 Alexion Pharma Inc Dosis y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (hpn) y el sindrome hemolitico uremico atipico (shua).
CN112512563A (zh) * 2018-08-01 2021-03-16 中外制药株式会社 用于治疗或预防c5相关疾病的药物组合物和治疗或预防c5相关疾病的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1705100A (en) 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
JP4768620B2 (ja) 2003-05-15 2011-09-07 ジェネンテック， インコーポレイテッド 敗血症の予防及び治療のための方法及び組成物
EP1874289A2 (en) 2005-03-29 2008-01-09 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
AU2006249835B2 (en) 2005-05-26 2011-09-08 Musc Foundation For Research Development Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
WO2007056227A2 (en) 2005-11-04 2007-05-18 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
BR122017024057B8 (pt) * 2006-03-15 2021-05-25 Alexion Pharma Inc anticorpo que se liga à c5 e composição farmacêutica compreendendo dito anticorpo e um veículo farmaceuticamente aceitável
NZ576195A (en) 2006-10-10 2012-04-27 Az Univ Amsterdam Complement inhibition for improved nerve regeneration
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
JP2010526074A (ja) 2007-04-30 2010-07-29 アルコン リサーチ， リミテッド 補体因子ｄのインヒビターを用いる加齢黄斑変性の処置
WO2008154251A2 (en) 2007-06-07 2008-12-18 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
EP2331561A4 (en) 2008-09-03 2013-02-27 Xenome Ltd PEPTIDE CONJUGATE LIBRARIES AND METHODS OF MAKING SAME
DK2894165T3 (da) 2008-11-10 2023-03-20 Alexion Pharma Inc Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
RU2600876C2 (ru) 2009-10-16 2016-10-27 Омерос Корпорейшен Способ лечения диссеминированного внутрисосудистого свертывания крови путем ингибирования masp-2 зависимой активации комплемента
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
US20110269807A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
EP3287142B1 (en) 2011-04-08 2021-08-04 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2014004733A1 (en) 2012-06-26 2014-01-03 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
WO2014078622A1 (en) 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
SG11201804721SA (en) 2015-12-16 2018-07-30 Ra Pharmaceuticals Inc Modulators of complement activity
JP7301741B2 (ja) * 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ

Also Published As

Publication number Publication date
BR112020010916A2 (pt) 2020-11-17
CA3084043A1 (en) 2019-06-13
CN111683672A (zh) 2020-09-18
IL274745A (en) 2020-07-30
WO2019112984A1 (en) 2019-06-13
JP2021505565A (ja) 2021-02-18
EP3720463A1 (en) 2020-10-14
TW201938184A (zh) 2019-10-01
SG11202005181RA (en) 2020-07-29
KR20200095485A (ko) 2020-08-10
US20210000927A1 (en) 2021-01-07
RU2020117578A (ru) 2022-01-14

Similar Documents

Publication Publication Date Title
MX2020005547A (es) Moduladores de la actividad del complemento.
MX2021010528A (es) Metodos y composiciones para el tratamiento de las ulceras.
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
MX2017013983A (es) Uso de agentes activos durante tratamientos quimicos.
PH12020500371A1 (en) Spirocycle compounds and methods of making and using same
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
EA201290286A1 (ru) Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2019009190A (es) Uso de gaboxadol en el tratamiento de tinnitus.
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
EA201991650A1 (ru) Способы лечения неврологических расстройств
MX2020011817A (es) Metodos para tratar el linfoma.
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
BR112019005539A2 (pt) métodos de tratamento de lesão renal aguda
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний
MX355853B (es) Composicion oftalmica para el tratamiento de infeccion ocular.
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
MX2016003525A (es) Agentes dirigidos contra una interaccion cis de molecula de orientacion repulsiva a (rgma) /neogenina o balsas lipidicas y uso de los mismos en metodos de tratamiento.
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.
MX2023012415A (es) Metodos de uso del dantroleno para tratar la exposicion a agente nervioso.
AR105142A1 (es) Métodos de tratamiento del glioblastoma multiforme con terapia de células t
EA202190891A1 (ru) Композиции и способы для контролируемой стимуляции яичников
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
EA202092554A1 (ru) Композиции для лечения кожных заболеваний